Bionomics Limited Enters Material Definitive Agreement

TL;DR

BIONOMICS LTD just signed a big deal, details TBD.

AI Summary

Bionomics Limited entered into a material definitive agreement on November 18, 2024. The filing does not disclose specific details of the agreement or any associated dollar amounts. The company is incorporated in Australia and its principal executive offices are located at 200 Greenhill Road, Eastwood, SA, Australia.

Why It Matters

This filing indicates a significant new contract or partnership for Bionomics Limited, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details about the material definitive agreement introduces uncertainty regarding its impact on the company.

Key Players & Entities

• Bionomics Limited (company) — Registrant
• November 18, 2024 (date) — Date of earliest event reported
• 200 Greenhill Road Eastwood, SA Australia (location) — Principal executive offices

FAQ

Key Financial Figures

• $2,000,000 — s in an aggregate offering amount up to $2,000,000 under the Sales Agreement. Sales of the
• $50,000 — es Agreement in an amount not to exceed $50,000 in the aggregate. The Company made cer
• $11,500,000 — having an aggregate sale price of up to $11,500,000 (the "Previous ATM Offering") pursuant

Filing Documents

• ea0221911-8k_bionom.htm (8-K) — 35KB
• ea022191101ex5-1_bionom.htm (EX-5.1) — 30KB
• ea022191101ex10-1_bionom.htm (EX-10.1) — 224KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• ex5-1_002.jpg (GRAPHIC) — 1KB
• 0001213900-24-100971.txt ( ) — 531KB
• bnox-20241118.xsd (EX-101.SCH) — 3KB
• bnox-20241118_lab.xml (EX-101.LAB) — 33KB
• bnox-20241118_pre.xml (EX-101.PRE) — 22KB
• ea0221911-8k_bionom_htm.xml (XML) — 4KB

01. Entry

Item 1.01. Entry Into a Material Definitive Agreement. ATM Offering On November 18, 2024, Bionomics Limited ("Bionomics" or the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("HCW" or the "Sales Agent"). Pursuant to the Sales Agreement, the Sales Agent will act as the Company's agent with respect to an offering and sale, at any time and from time to time, of the Company's American Depository Shares, no par value per share (the "Shares"). The Company has authorized the sale, at its discretion, of Shares in an aggregate offering amount up to $2,000,000 under the Sales Agreement. Sales of the Shares, if any, will be made in "at the market offerings" as defined in Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"). The Sales Agent will use commercially reasonable efforts consistent with normal trading and sales practices. The offer and sale of the Shares will be made pursuant to the Company's shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission ("SEC") on November 18, 2024 (File No. 333-283306, the "Registration Statement"), and a related prospectus, as supplemented by a prospectus supplement pursuant to Rule 424(b) under the Securities Act. We will not make any offers or sales of ADS's or any other securities registered thereunder unless and until the Registration Statement is declared effective by the SEC. We are not obligated to make any sales of Shares under the Sales Agreement and no assurance can be given that we will sell any Shares under the Sales Agreement, or, if we do, as to the price or amount of Shares that we will sell, or the dates on which any such sales will take place. The Company or the Sales Agent, under certain circumstances and upon notice to the other, may suspend the offering of the Shares under the Sales Agreement. The offering of the Shares pursuant to the Sales Agreement will terminate upon the

01. Financial

Item 9.01. Financial (d) Exhibits: Exhibit Number Description 5.1 Legal Opinion of Johnson Winter Slattery 10.1 At The Market Offering Agreement, dated as of November 18, 2024, between Bionomics Limited and H.C. Wainwright & Co., LLC 23.1 Consent of Johnson Winter Slattery (included in Exhibit 5.1) 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) 2

SIGNATUREs

SIGNATUREs Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIONOMICS LIMITED Date: November 21, 2024 By: /s/ Spyridon Papapetropoulos Spyridon Papapetropoulos President and Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR